Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical ...

Chronic hepatitis delta virus (HDV) infection has its first FDA-approved treatment, after the agency granted accelerated approval to bulevirtide (Hepcludex) injection for adults without cirrhosis or ...

US FDA grants accelerated approval to Gilead’s Hepcludex for the treatment of chronic hepatitis delta virus: Foster City, California Tuesday, May 26, 2026, 10:00 Hrs [IST] Gilea ...

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir; Data on the preclinical characteristics of the Al ...

Jody Baron and Gabi Fragiadakis discover why some people with chronic Hepatitis B are cured after they're taken off of ...

Hepatitis B virus (HBV) infection acquired at birth or during early infancy can lead to lifelong health complications, ...

Chronic HDV occurs only with HBV and confers markedly higher risks of rapid progression, cirrhosis, liver failure, and ...

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 ...

The patient had been living with Hepatitis B for several years and was diagnosed with HIV around three years ago. Over time, ...

FDA approves 1st chronic HDV treatment Hepcludex to reduce virus levels and improve liver function in adults with hepatitis delta virus.